Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 1, 2009, Pages 62-66

  Miller, Lori M ^a   Mayer, Scott C ^a   Berger, Dan M ^b   Boschelli, Diane H ^b   Boschelli, Frank ^b   Di, Li ^a   Du, Xuemei ^b   Dutia, Minu ^b   Floyd, Middleton B ^b   Johnson, Mark ^a   Kenny, Cynthia Hess ^b   Krishnamurthy, Girija ^b   Moy, Franklin ^a   Petusky, Susan ^a   Tkach, Diane ^b   Torres, Nancy ^b   Wu, Biqi ^b   Xu, Weixin ^a  

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

'Hit to Lead' investigations; Cyanoquinoline; IGFR inhibitor

Indexed keywords

3 CYANOQUINOLINE DERIVATIVE; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR INHIBITOR; INSULIN RECEPTOR; QUINOLINE DERIVATIVE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; HUMANS; NITRILES; QUINOLINES; RECEPTOR, IGF TYPE 1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57949114351     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.037     Document Type: Article

References (22)

1. Randhawa R., and Cohen P. Mol. Genet. Metab. 86 (2005) 84
2. Chng W.J., Gualberto A., and Fonseca R. Leukemia 20 (2006) 174
3. Strömberg T., Ekman S., Girnita L., Dimberg L.Y., Larsson O., Axelson M., Lennartsson J., Hellman U., Carlson K., Österborg A., Vanderkerken K., Nilsson K., and Jernberg-Wiklund H. Blood 107 (2006) 669
4. Breuhahn K., Longerich T., and Schirmacher P. Oncogene 25 (2006) 3787
5. Fang J., Zhou Q., Shi X., and Jiang B. Carcinogenesis 28 (2007) 713
6. Riedemann J., and Macaulay V.M. Endocr. Related Cancer 13 (2006) 33
7. De Meyts P., and Whittaker J. Nat. Rev.: Drug Discov. 1 (2002) 769
8. Mayer S.C., Banker A.L., Boschelli F., Di L., Johnson M., Kenny C.H., Krishnamurthy G., Kutterer K., Moy F., Petusky S., Ravi M., Tkach D., Tsou H.-R., and Xu W. Bioorg. Med. Chem. Lett. 12 (2008) 3641
9. Zhang N., Wu B., Eudy N., Wang Y., Ye F., Powell D., Wissner A., Feldberg L.R., Kim S.C., Mallon R., Kovacs E.D., Toral-Barza L., and Kohler C.A. Bioorg. Med. Chem. Lett. 11 (2001) 1407
10. Wissner, A.; Tsou, H.-R.; Berger, D. M.; Floyd, M. B., Jr.; Hamann, P. R.; Zhang, N.; Salvati, M. E.; Frost, P. U.S. Patent 6,288,082, 2001.
11. Berger D., Dutia M., Powell D., Wu B., Wissner A., Boschelli D.H., Floyd M.B., Zhang N., Torres N., Levin J., Du X., Wojciechowicz D., Discafani C., Kohler C., Kim S.C., Feldberg L.R., Collins K., and Mallon R. Bioorg. Med. Chem. Lett. 13 (2003) 3031
12. Boschelli, D. H.; Wang, Y. D.; Johnson, S. L.; Berger, D. M. U.S. Patent 6, 780, 996, 2004.
13. 2-TRDIYETDYYRK-OH) for 90 min at room temperature. The final ATP concentration was 100 μM.
14. Jamieson E.R., Jacobson M.P., Barnes C.M., Chow C.S., and Lippard S.J. J. Biol. Chem. 274 (1999) 12346
15. 2. Increasing concentrations of the inhibitor quenched the fluorescence and the changes were used to determine the binding affinity.
16. Xu, W.; Dwyer, B.; Moy, F.; Mayer, S.; Boschelli, F.; Tkach, D.; Bean, K.; Mosyak, L.; Wilhelm, J. Presented at the 5th Annual Meeting of Protein Kinase Targets & Structure-Based Design, Boston, MA, June 2007; poster session.
17. RCSB Protein Data Bank (PDB) deposition number 3F5P.
18. 50s were determined using model 63 of the LSW Excel plug-in.
19. 6)
20. Boschelli D.H., Wu B., Ye F., Durutlic H., Golas J.M., Lucas J., and Boschelli F. Bioorg. Med. Chem. 16 (2008) 405
21. Hopper D.W., Dutia M., Berger D.M., and Powell D.W. Tet. Lett. 49 (2008) 137
22. Pautsch A., Zoephel A., Ahorn H., Spevak W., Hauptmann R., and Nar H. Structure 9 (2001) 955